It was a pleasure to talk to Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College, London, UK) around his recent analysis of the NAVIGATOR data, investigating the effect of tezepelumab in OCS-dependent severe asthma patients (Clinical Trial Identifier: NCT03347279).
The abstract ‘Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the Phase 3 NAVIGATOR Study.‘ (ABSTRACT NUMBER: A1442) was presented at ATS 2021 International Conference, 14-19 May, 2021.
- What adverse events are associated with long-term maintenance oral corticosteroids (mOCS) in patients with severe asthma and how does this impact on quality of life and healthcare costs? (0:10)
- What is the rationale for the use of tezepelumab in the treatment of patients with severe asthma? (1:16)
- What have the PATHWAY and NAVIGATOR studies taught us about the efficacy and safety of tezepelumab in this indication? (2:06)
- Could you tell us a little about the objectives and design of your recent analysis of the NAVIGATOR data? (2:45)
- What were the findings of this analysis and what are their implications for patients with severe, OCS-dependent asthma? (3:36)
Disclosures: Andrew Menzies-Gow has participated in research with Astra Zeneca for which his institution has been renumerated and attended advisory boards, has consultancy agreements with and received speaker fees from Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!